Study Title: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Frank Brescia, at bresciaf@musc.edu.Study Coordinator, Zachary Bargeloh, at bargeloh@musc.edu.Trial opened at the following institutions: Medical University of South Carolina